Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 12;75(8):1453-1456.
doi: 10.1093/cid/ciac124.

Lower Rates of Emergency Department Visits and Hospitalizations Among Patients With Chronic Hepatitis C With Sustained Virological Response to Interferon-Free Direct-Acting Antiviral Therapy (2014-2018)

Stuart C Gordon  1   2 , Eyasu H Teshale  3 , Philip R Spradling  3 , Anne C Moorman  3 , Joseph A Boscarino  4 , Mark A Schmidt  5 , Yihe G Daida  6 , Loralee B Rupp  7 , Sheri Trudeau  8 , Jiaqi Zhang  8 , Mei Lu  8 ; CHeCS Investigators
Collaborators, Affiliations

Lower Rates of Emergency Department Visits and Hospitalizations Among Patients With Chronic Hepatitis C With Sustained Virological Response to Interferon-Free Direct-Acting Antiviral Therapy (2014-2018)

Stuart C Gordon et al. Clin Infect Dis. .

Abstract

We compared rates of emergency department visits and hospitalizations between patients with hepatitis C virus who achieved sustained virological response after direct-acting antiviral therapy (case patients) and matched controls. Among 3049 pairs, case patients demonstrated lower rates of liver-related emergency department visits (P = .01) than controls; all-cause and liver-related hospitalization rates and number of hospitalized days were also lower in case patients (P < .001).

Keywords: ED; HCV; SVR; healthcare utilization; race.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. C. G. receives grant/research support from AbbVie Pharmaceuticals, Conatus Pharmaceuticals, Eiger Pharmaceuticals, Eli Lilly, Genfit, Gilead Sciences, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, CymaBay, and Viking Therapeutics and receives royalties or licenses from UpToDate publication for article contributions. J. A. B., M. A. S., Y. G. D., L. B. R., and M. L. receive research grant support from Gilead Sciences and Intercept Pharmaceuticals. J. A. B. also received grants (paid to his institution), outside the scope of this work, from Purdue Pharma, Pfizer Pharma, the US Department of Defense, and the US Food and Drug Administration. M. A. S. received grants (paid to his institution), outside the scope of this work, from Vir Biotechnology, the National Institutes of Health, CDC, and P95. L. B. R. also received grants (paid to her institution), outside the scope of this work, from AbbVie and GlaxoSmithKline. S. T. and J. Z. received grants (paid to their institution), outside the scope of this work, from Intercept Pharmaceutical, AbbVie, and GlaxoSmithKline. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types